© 2024 Corcept Therapeutics, Incorporated
Pharmacokinetics of the Selective Glucocorticoid Receptor Modulator Miricorilant in Healthy Volunteers and Patients with Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Custodio et al. • 2024 • EASL 2024 Congress
MONARCH: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Miricorilant in Adult Patients with Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (NASH/MASH)
Alkhouri et al. • 2024 • NASH-TAG 2024 Congress
Miricorilant Reduced Liver Fat and Cardiometabolic Disease Markers in a Phase 1b, Open-Label Dose-Finding Study in Patients with Non-Alcoholic Steatohepatitis (NASH)
Alkhouri et al. • 2024 • NASH-TAG 2024 Congress
Miricorilant reduced liver fat and cardiometabolic disease markers in a phase 1b, open-label dose-finding study in patients with non-alcoholic steatohepatitis (NASH)
Alkhouri et al. • 2023 • AASLD 2023 Congress
Miricorilant, a selective GR modulator, induced a rapid and significant reduction in liver fat content in a randomized, placebo-controlled phase 2a study in patients with nonalcoholic steatohepatitis
Kowdley et al • 2021 • The Liver Meeting 2021 (American Association for the Study of Liver Diseases)
Effect of Miricorilant, a Selective Glucocorticoid Receptor Modulator, on Olanzapine-Associated Weight Gain in Healthy Subjects: A Proof-of-Concept Study
Hunt et al • 2021 • Journal of Clinical Psychopharmacology: August 6, 2021
Reversal of Antipsychotic-Induced Weight Gain in Rats with Miricorilant, a Selective Glucocorticoid Receptor (GR) Modulator
Lee et al. • 2020 • 2020 Annual Meeting - American Psychiatric Association (APA)
The Liver Meeting 2021 (American Association for the Study of Liver Diseases)
Kowdley et al • 2021 •
Selective Glucocorticoid Receptor Modulation Prevents and Reverses Nonalcoholic Fatty Liver Disease in Male Mice
Koorneef et al. • 2018 • Endocrinology. 2018, 159(12):3925–3936